ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) is a 5-year prospective randomised open blinded endpoint design (PROBE) controlled trial of the prevention of coronary heart disease and other vascular events by blood pressure lowering, and uses a factorial design to assess the same endpoints by cholesterol lowering with a statin.
It is the first trial designed to evaluate benefits of specific combinations of treatment of hypertension (diuretic + b-blocker vs calcium channel blockers + ACE inhibitors) and one of only two major trials powered to detect differences in coronary heart disease outcome of two different treatment regimens. A total of more than 19,000 patients have been recruited in United Kingdom, Ireland, Denmark, Iceland, Finland, Norway and Sweden. St George's is one of the 26 Regional Recruiting Centres for UK and Ireland and contributes with approximately 300 patients recruited and under follow-up.
The study is coordinated by groups in London (at Imperial College School of Medicine) and Goteborg, Sweden. Trial recruitment began in February 1998 and was completed in May 2000. Follow up is for an average of 5 years.
- Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank JK, Sever PS, Feder G on behalf of ASCOT investigators. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomised in the ASCOT Trial. Am J Hypertens 2010; 23: 1023-30
- Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, for the ASCOT Investigators*. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366: 895-906
- Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, for the ASCOT Investigators*. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361:1149-58
Regional Recruiting Centre
F P Cappuccio (WMS)
G A MacGregor
N D Markandu
C Carney (SGUL)
Pfizer Inc (via ICSM)